Articles tagged with Chemotherapy
A new biomedical implant, microMESH, has been developed to treat glioblastoma multiforme. The device wraps around tumor masses, delivering drugs in a controlled, prolonged manner, increasing therapeutic efficacy.
Researchers at Linköping University and Medical University of Graz developed an ion pump that can deliver chemotherapy agents like gemcitabine directly into the brain with high precision. This method may provide a more effective treatment for glioblastoma, a type of brain tumor.
Researchers developed a two-pronged approach targeting cancer progression and cell destruction, leveraging cathepsin S and p21 BAX proteins to treat kidney cancer. The novel peptide CS-PEP1 inhibits these proteins, encouraging cancer cell death and overcoming molecular resistance found in conventional chemotherapy treatment.
A new study suggests that immunotherapies combined with phenformin may be an effective way to fight cancer. Researchers found that phenformin has structural and therapeutic advantages over its sister compound metformin, which was previously used as an anti-diabetic agent.
Researchers identified a novel drug duo that exploits a weakness in SCLC's reproduction process, increasing replication stress and damaging DNA. The berzosertib-topotecan combination helped improve symptoms in over one-third of patients in a clinical trial.
Research from Queen Mary University of London reveals that chemotherapy activates immune cells within the tumor microenvironment to fight against cancer. Macrophages switched from pro-tumour to anti-tumour mode after chemotherapy, stimulating patient's immune response and potentially improving survival outcomes.
Researchers at Case Western Reserve University developed a novel transdermal mixture of terbinafine and clotrimazole to combat Candida auris, a highly resistant fungus. The study found that this formulation can effectively reduce the presence of C. auris on skin and prevent its spread.
Researchers at Niigata University have identified a protein biomarker, APM2, that can indicate the permissible level of the chemotherapeutic drug cisplatin. The study found a significant relationship between high APM2 expression and cisplatin resistance in liver and gastric cancer cells.
A new pilot study suggests that restricting calories, reducing fat and sugar intake, and increasing physical activity can improve the effectiveness of chemotherapy for older children and adolescents with leukemia. The intervention showed promise in reducing minimal residual disease, a strong predictor of relapse.
Researchers at WashU Medicine found that administering chemotherapy drug temozolomide in the morning improved overall survival by about 4 months compared to evening, with an average increase of 3.5 months in patients with MGMT methylated tumors. The study suggests that adjusting timing of standard treatment could enhance effectiveness.
A case of atezolizumab-induced autoimmune diabetes mellitus presenting with diabetic ketoacidosis is reported, highlighting the importance of monitoring blood glucose levels in patients treated with PD-L1 inhibitors. The patient's condition was successfully managed with cessation of atezolizumab treatment and insulin therapy.
A new study from the University of Arizona Department of Surgery found that pancreatic cancer patients who undergo chemotherapy followed by resection live an average of 19.75 months, compared to 10.12 months for those who received only chemotherapy. The researchers suggest that surgery can improve survival even in difficult cases.
A team at Washington University in St. Louis has developed an imaging technique using acoustic resolution photoacoustic microscopy co-registered with ultrasound and paired with deep learning to differentiate between residual tumors and healthy tissue in rectal cancer patients after chemotherapy and radiation. This technique shows promi...
A retrospective study found that folinic acid with fluorouracil improves progression-free and overall survival in metastatic colorectal cancer patients. The combination also shows a clear clinical benefit regardless of RAS mutational status or tumor side. This suggests folinic acid may be a valuable addition to chemotherapy protocols.
Researchers at the University of Queensland have discovered that an anti-inflammatory drug called anakinra can reduce the awful nerve symptoms associated with vincristine chemotherapy. The study found that anakinra substantially reduced neuropathic pain without reducing the effectiveness of the treatment.
Researchers at Weill Cornell Medicine found that cancer cells can dodge chemotherapy by entering a state of hibernation, or senescence, which enables them to survive aggressive treatments. This discovery has implications for developing new drug combinations that could block senescence and make chemotherapy more effective.
Researchers assessed tumor cell isolation and in vitro proliferation assays to predict chemotherapy response in ovarian cancer. In 12 of 14 cases, in vitro drug sensitivity correlated with clinical outcome.
Researchers from Osaka University have identified the molecular mechanism underlying bone marrow regeneration after chemotherapy. They found that group 2 innate lymphoid cells produce granulocyte-macrophage colony-stimulating factor to aid in HSPC recovery, and their transfer accelerates hematopoietic recovery.
A recent study has identified potential risk factors for chemotherapy-induced peripheral neuropathy (CIPN), including age, body mass index (BMI), and low haemoglobin levels. Patients who are older, overweight, or have lower red blood cell counts may be more at risk of developing debilitating nerve damage following chemotherapy.
Researchers have created a boron-containing chemical group that is 10,000 times more stable than its predecessors. This new group, called benzoxaboralone, can be added to compounds to provide desirable attributes such as improved protein-binding strength.
Scientists at Far Eastern Federal University have developed a compound that kills prostate cancer cells while also activating an enzyme protecting them. The compound, 3,10-dibromofascaplysin, works well in combination with approved anticancer drugs and is being studied for its potential to reduce side effects.
A new glioma-targeted nano-therapeutic developed by UH researcher Sheereen Majd delivers the highly toxic anti-cancer drug Dp44mT directly to brain tumor cells, reducing toxicity and improving treatment outcomes.
A study published in Oncotarget found that hemoglobin-based oxygen carriers increase chemotherapy effectiveness in non-small cell lung cancer. PolyHb administration attenuates tumor growth without alleviating hypoxia, suggesting a potential strategy to enhance cisplatin sensitivity.
A new class of antibiotic-drug conjugate (ADC) drugs has been found to significantly increase the survival rate of patients with bladder cancer. The study, led by Queen Mary University of London, showed that the drug reduced the risk of death by 30% compared to chemotherapy, with a median survival time of approximately 13 months.
A Mayo Clinic team developed an ionic liquid formulation that killed cancer cells and allowed for uniform distribution of a chemotherapy drug into liver tumors and other solid tumors. This discovery could solve challenges in drug delivery to tumors, particularly for patients with liver cancer awaiting a transplant.
A liquid formulation called LATTE has been shown to kill liver cancer cells and potentiate chemotherapy treatments in mice, rabbits, pigs, and human tumor samples. The treatment could provide a safer alternative to traditional methods like thermal ablation, which can be resource-intensive and damage surrounding tissues.
Researchers found six FDA-approved drugs that can inhibit protein-cutting enzymes essential for SARS-CoV-2 replication. The study's findings have the potential to develop a broad spectrum of antiviral drugs and prevent future pathogenic SARS-CoV strains.
Groundbreaking evidence reveals scalp cooling reduces chemotherapy drug absorption by hair follicle cells. This mechanism explains the treatment's cytoprotective effect and supports its clinical efficacy. The study provides new insights into scalp cooling's potential for reducing hair loss in cancer patients.
Researchers at the University of South Australia have developed a new 3D printed oesophageal stent that contains an active pharmaceutical ingredient, allowing for sustained anti-cancer medication delivery directly to the cancer site. This technology has the potential to revolutionize treatment for patients with oesophageal cancer.
Researchers report a promising therapeutic approach combining PD-1 and VEGF inhibitors with chemotherapy to control cholangiocarcinoma progression. This treatment resulted in significant reduction of lung lesions and stabilization of liver lesions, suggesting potential for improved patient survival.
Researchers analyzed mRNA expression levels of molecular markers ERCC1 and thymidylate synthase in patients with resected stage II-III non-small cell lung cancer. The study found no correlation between these markers and overall survival, contradicting previous hopes for a personalized chemotherapy approach.
Two ADAURA analyses presented at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer (WCLC) Singapore support the use of Osimertinib as a new treatment strategy for patients with surgically resected, Stage IB to IIIA non-small cell lung cancer. The data show significant disease-free surviva...
Researchers at Concordia University discover that melatonin reduces cysts in the renal tubules of fruit flies, a finding that may improve treatments for polycystic kidney disease. The study builds on previous work and suggests a targeted approach to treating this genetic chronic disease.
Researchers develop innovative approach to treating bone tumors by starving cancer cells of their energy source, potentially replacing toxic chemo with a less harmful treatment. The two-drug combination showed promise in mice studies, outperforming a commonly used chemotherapy drug without severe side effects.
Researchers developed a BCL strategy to generate highly potent tumor-targeted drugs from non-toxic compounds within the tumor, avoiding decomposition and side effects. The targeting drug Ru-rhein exhibits high anti-cancer activity against lung cancer cells while being non-toxic to normal cells.
Scientists have discovered a way to block doxorubicin from accessing the heart by introducing another anti-cancer drug, nilotinib, before chemo. This intervention may prevent cardiac injury caused by doxorubicin, used to treat various solid tumors and blood cancers.
Researchers at Kanazawa University have found that combining alectinib with ixazomib, a proteasome inhibitor, restores the efficacy of alectinib in patients with NSCLC who develop secondary TP53 mutations. This combination therapy has shown promising results in preclinical trials.
A randomized clinical trial found that pre-surgery chemotherapy did not improve survival rates in early-stage pancreatic cancer patients, but it is a safer alternative. The study paved the way for further treatment testing and molecular analysis of tumor tissue.
A new method, D2O-CANST-R, allows for rapid and precise tracking of metabolic changes in cancer cells at the single-cell and single-organelle level. This approach has the potential to reveal the metabolism in a cancer cell with very fine details and distinguish between effective and ineffective drugs.
Researchers at UBC Okanagan have developed a novel method to remove anti-cancer drugs like methotrexate from wastewater using porous metal-organic frameworks. The technique is affordable, effective, and has high adsorption capacity, making it an impressive candidate for improving wastewater systems.
Research at Charité - Universitätsmedizin Berlin found that patients' immune systems before chemotherapy determine treatment success in bladder cancer. High levels of CXCL11 and CXCR3alt receptors indicate a strong immune response, leading to increased survival rates.
A new risk assessment tool, CARG-BC Score, helps oncologists make personalized treatment recommendations for elderly patients with early-stage breast cancer. The score combines eight disease and patient-reported predictors to predict the likelihood of severe chemotherapy side effects.
Researchers at Massachusetts General Hospital have found that reprogramming the connective tissue microenvironment of a liver cancer can inhibit its progression and resistance to chemotherapy. Blocking placental growth factor (PlGF) with antibodies reduces production of connective tissue and increases survival in mice with liver cancer.
Researchers have found that cancer cells can enter a slow-dividing state to survive chemotherapy, similar to an embryonic survival program in mammals. Targeting these sleeping cells with novel therapies may prevent cancer regrowth and overcome drug resistance.
Researchers found that statin users were 55% less likely to be treated at the hospital for heart failure after anthracycline treatment, and 54% less likely with trastuzumab treatment. Statins may be a potential intervention for preventing heart failure in patients receiving chemotherapy.
A new UCL study found that combining heat treatment with chemotherapy delivered via magnetic nanoparticles killed cancer cells more effectively than chemotherapy alone. The therapy showed synergistic effects, enhancing the effectiveness of both treatments when combined. Heat treatment can reduce side effects by targeting only cancer ce...
A new study from the University of East Anglia estimates that breast cancer chemotherapy in the UK results in over £248 million in annual costs. These costs include lost productivity and personal expenses such as wigs and medication. Better targeting of treatment could help reduce these unnecessary costs.
A novel virtual screening strategy identified pralatrexate as a promising treatment for Covid-19. Lab experiments showed that the chemotherapy medication inhibited viral replication more effectively than remdesivir.
A University of Cincinnati study found that remdesivir permanently stops the activity of an enzyme needed for medication breakdown, increasing toxicity with certain heart and anticancer drugs. The researcher recommends using remdesivir with caution in patients with specific enzymes and in proper dosages.
A team of researchers has identified a protein called RFWD3 that plays a critical role in recruiting DNA repair and signaling factors. The discovery could lead to new methods to inhibit these repair processes, making chemotherapy more efficient and reducing side effects.
Researchers found a drug used to treat pulmonary hypertension significantly reduced tumor cell migration and invasion, and showed promise in slowing breast cancer progression. The study aims to conduct clinical trials with patients undergoing chemotherapy to further investigate the treatment's effectiveness.
Researchers developed a new model to predict kidney function in cancer patients, enabling more accurate chemotherapy dosing and minimizing harm. The model takes into account various factors like age, gender, and body mass index, providing clinicians with a valuable tool for guiding treatment decisions.
Researchers found that adding an immune checkpoint inhibitor to standard chemotherapy for patients with early-stage breast cancer does not decrease their ability to perform daily activities. The study, based on data from the IMpassion031 trial, showed increased response rates and no significant impact on quality of life.
A new clinical trial suggests that postmenopausal patients with hormone receptor-positive and HER2-negative breast cancer and a low recurrence score of 25 or lower may safely avoid chemotherapy. In contrast, premenopausal patients who receive chemotherapy show improved invasive disease-free survival and overall survival rates.
A clinical trial found that postmenopausal women with low-risk breast cancer can forego chemotherapy without compromising their treatment outcomes. In contrast, premenopausal women with the same disease characteristics benefit from chemotherapy, suggesting a potential age-related difference in treatment effectiveness.
A new cancer therapy approach combines gemcitabine chemotherapy with celecoxib, an anti-inflammatory medication, to activate the immune system and fight cancer. The combination has shown potential in improving the percentage of patients who respond to immunotherapy drugs.
The study showed that the combination of chemotherapy and blinatumomab resulted in increased survival rates and achieved a high rate of MRD negativity for patients with Ph-negative B-cell ALL. This treatment approach has the potential to improve long-term outcomes for these patients.
The combination of venetoclax with chemotherapy improves outcomes for patients with AML and MDS, with a promising overall response rate and acceptable safety profile. Venetoclax also demonstrates efficacy in treating high-risk MDS when combined with azacitidine.
Australian researchers discovered a protein that protects kidney cells from 'bystander' damage caused by chemotherapy or radiotherapy. The study found that inhibiting BCL-XL could safely use in laboratory models alone or with other cancer therapies to prevent kidney damage, a common side effect of cancer treatments.
Researchers designed DNA-based nanogels that break down and release chemotherapeutic contents only in cancer cells. The nanogels use biomarkers like FEN1 to differentiate between healthy and cancerous cells, reducing the impact on normal cells.